Indications for ERAXIS:
Candidemia and other Candida infections (intra-abdominal abscess, peritonitis) in patients ≥1month of age. Esophageal candidiasis in adults.
Limitations of Use:
Not been studied in those with endocarditis, osteomyelitis, and meningitis due to Candida, or in sufficient numbers of neutropenic patients to determine efficacy. Dosage for treatment of Candida dissemination into the CNS and the eye has not been established.
Give by IV infusion; max rate 1.1mg/min. Candidemia and other Candida infections: 200mg on day 1, then 100mg/day for at least 14 days after last positive culture. Esophageal candidiasis: 100mg on day 1, then 50mg/day for at least 14 days and at least 7 days after symptom resolution.
<1month: not established. Give by IV infusion; max rate 1.1mg/min. ≥1month: 3mg/kg (max 200mg) on day 1, then 1.5mg/kg/day (max 100mg/day) for at least 14 days after last positive culture.
Hereditary fructose intolerance (HFI).
Follow-up if abnormal LFTs develop; evaluate for continued therapy. Discontinue and treat appropriately if anaphylactic reactions occur. Obtain history of HFI symptoms prior to initiation (esp. children). Neonates: risk of polysorbate toxicity. Pregnancy. Nursing mothers.
Glucan synthesis inhibitor (echinocandin).
Hypokalemia, GI upset, pyrexia, insomnia, hypotension, anemia, headache, dyspepsia, oral candidiasis; children: also abdominal pain, thrombocytopenia, increased ALT/AST, hypoglycemia, epistaxis, rash.